Thermalin

Thermalin is developing next-generation insulin solutions for people with Type 1 (T1D) and Type 2 diabetes (T2D). Thermalin's preclinical programs include ultra-rapid-acting insulin, insulins that never need refrigeration, glucose-responsive insulin, and a once-a-week insulin patch. Thermalin's new molecular designs are the creation of Dr. Michael Weiss at Case Western Reserve University School of Medicine (http://case.edu/medicine) and exclusively licensed to Thermalin. Thermalin and Dr. Weiss's work has been supported by numerous academic and SBIR grants from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the US NIH, and is particularly indebted to Dr. Guillermo Arreaza-Rubin, whose inspirational leadership at NIDDK has been instrumental in advancing academic and industry progress on new therapies for Diabetes (www.niddk.nih.gov). Thermalin and Dr. Weiss have also benefited from generous support from the JDRF (www.jdrf.org). Dr. Weiss gratefully acknowledges additional generous support by the Leona M. and Harry B. Helmsley Charitable Trust (www.helmsleytrust.org).